AstraZeneca PLC (AZN) annual results, year to 31 December 2020: revenue USD 26,617 million, from the 20-F
AstraZeneca PLC files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2020 it reported revenue of USD 26,617 million, up 9.2% on the year before. Its profit attributable to shareholders was USD 3,196 million, up 139.4%, and diluted earnings per share USD 2.44.
The year to 31 December 2020, against the year before
| Year to | Dec 2019 | Dec 2020 |
|---|---|---|
| Revenue | 24,384 | 26,617 |
| Cost of sales | 4,921 | 5,299 |
| Gross profit | 19,463 | 21,318 |
| Research and development | 6,059 | 5,991 |
| Selling, general and administrative | 11,682 | 11,294 |
| Operating profit | 2,924 | 5,162 |
| Finance costs | 1,432 | 1,306 |
| Profit before tax | 1,548 | 3,916 |
| Income tax | 321 | 772 |
| Profit for the year | 1,227 | 3,144 |
| Profit attributable to shareholders | 1,335 | 3,196 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2019 | Dec 2020 |
|---|---|---|
| Cash from operations | 2,969 | 4,799 |
| Purchase of property, plant and equipment | 979 | 961 |
| Free cash flow | 1,990 | 3,838 |
| Dividends paid | 3,592 | 3,572 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2019 | Dec 2020 |
|---|---|---|
| Total assets | 61,377 | 66,729 |
| Equity attributable to shareholders | 13,127 | 15,622 |
| Cash and cash equivalents | 5,369 | 7,832 |
| Borrowings, as filed | 18,227 | 20,380 |
| Lease liabilities | 675 | 681 |
| Trade and other receivables | 5,761 | 7,022 |
| Inventories | 3,193 | 4,024 |
| Goodwill | 11,668 | 11,845 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2019 | Dec 2020 |
|---|---|---|
| Gross margin | 79.8% | 80.1% |
| Operating margin | 12.0% | 19.4% |
| Net margin | 5.5% | 12.0% |
| Free cash flow margin | 8.2% | 14.4% |
| Return on year-end equity | 10.2% | 20.5% |
| Effective tax rate | 20.7% | 19.7% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021
- Year to 31 December 2020, this page
- Year to 31 December 2019
- Year to 31 December 2018
- Year to 31 December 2017
- Year to 31 December 2016
- Year to 31 December 2015
Source
20-F for the year to 31 December 2020, filed 21 February 2023, accession 0001104659-23-023818: the filing on EDGAR. All of AstraZeneca PLC's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.